Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05370079

Control Cohort CTRL COH

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis Amyotrophic Lateral Sclerosis Astrocytoma Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Glioblastoma Glioma Metabolic Diseases Motor Neuron Disease Movement Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nervous System Diseases Neurodegenerative Diseases Neuroectodermal Tumors Neuromuscular Diseases Nutritional and Metabolic Diseases Parkinson Disease Parkinsonian Disorders Proteostasis Deficiencies Spinal Cord Diseases Synucleinopathies TDP-43 Proteinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospices Civils de Lyon

Bron, 69500, France

Location status: Recruiting

Location contact

Jerome HONNORAT

PRINCIPAL_INVESTIGATOR

Jerome HONNORAT, Pr

CONTACT

[email protected]

(33) 4 72 35 78 06

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patient with consent
  • patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.

Exclusion criteria

  • refusal consent
  • patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
  • patient under guardianship

Treatment and study plan

Collection of biological sample (blood and/or CSF)

Biological

Blood sample will be collected one time for each patient:

2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube

If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).

Primary outcomes

  1. Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)

    Time frame: 15 minutes

    Numbers of samples collected and patients included in the cohort

Secondary outcomes

  1. Description of genetic analysis

    Time frame: Data collecting: 3 years Data analysis: 2 years

    Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)

Study contacts

Contact information is provided by the study sponsor or research team.

Géraldine Picard, CRA

CONTACT

[email protected]

(33) 4 72 35 58 42

Jerome Honnorat, Pr

CONTACT

[email protected]

(33) 4 72 35 78 06

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: CTRL COH

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
May 11, 2022
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.